Quidel to Participate in the CEO Series Conference Call Hosted by Canaccord Genuity
September 08 2017 - 9:00AM
Business Wire
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider
of rapid diagnostic testing solutions, cellular-based virology
assays and molecular diagnostic systems, announced today that
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will participate in the CEO
Series Conference Call, hosted by Canaccord Genuity on Monday,
September 11, 2017 at 11:00 a.m. Eastern time (8:00 a.m. Pacific
time).
During the presentation, the company will discuss business and
financial developments and trends, which may include discussion of
the Company’s pending acquisition of assets of the Triage® MeterPro
cardiovascular and toxicology business, and the Triage BNP business
from Alere Inc. The company's statements may contain or constitute
material information that has not been previously disclosed.
The conference call may be accessed by dialing (877) 930-5791
for participants in the U.S./Canada or (253) 336-7286 for
participants outside the U.S./Canada using the required conference
ID 83358293. A live webcast and audio archive of the conference
call will be available via the Investor Relations section of the
company’s Web site at http://ir.quidel.com
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel’s research and development engine is
also developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170908005445/en/
For Quidel CorporationRandy StewardChief Financial Officer(858)
552-7931orVictoria SivraisClermont Partners(312)
690-6004vsivrais@clermontpartners.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2024 to May 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2023 to May 2024